Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GLA | P06280 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 6/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | CDC25A | P30304 | 1/20 | 0.43 |
| ▸ | CDC25C | P30307 | 1/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.43 |
| ▸ | PKLR | P30613 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5112338 | 0.90 | KDM4E (0.52) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL5107324 | 0.82 | MAOA (0.54) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL5113287 | 0.82 | ESR1 (0.45) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL16847176 | 0.82 | ESR1 (0.50) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL5113933 | 0.80 | MIF (0.47) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL5108590 | 0.75 | MAOA (0.48) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL5120752 | 0.75 | CA12 (0.44) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL4742427 | 0.73 | KDM4E (0.60) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL31464865 | 0.73 | KDM4E (0.60) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL5122044 | 0.73 | MAOA (0.51) | KDM4EALDH1A1GLAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329654-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-12 | — | — | US | disclosed |
| US-7329654-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-12 | — | — | US | disclosed |
| US-7329654-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-12 | — | — | US | disclosed |
| US-7105679-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | KANOJIA RAMESH M | 2006-09-12 | — | — | US | disclosed |
| EP-1467998-B1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2006-03-29 | — | — | EP | disclosed |
| EP-1569939-A1 | NOVEL HETEROATOM CONTAINING TETRACYCLIC DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040259915-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | KANOJIA RAMESH M (US) | 2004-12-23 | — | — | US | disclosed |
| WO-2004050660-A1 | NOVEL HETEROATOM CONTAINING TETRACYCLIC DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259915-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | KDM4E 2868/4885ALDH1A1 2801/4885GLA 1009/4885 |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | KDM4E 2868/4885ALDH1A1 2801/4885GLA 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.